Literature DB >> 2749102

Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome.

S V Komshian1, A K Uwaydah, J D Sobel, L R Crane.   

Abstract

We reviewed 135 cases of candidemia occurring between 1983 and 1986 to examine oncologic and nononcologic populations and assess factors for survival. Candida albicans was the most common species (51%); Candida tropicalis occurred most frequently in leukemia patients (57%), whereas Candida parapsilosis and Torulopsis glabrata were associated with solid tumors and nononcologic diseases. Risk factors identified were: preceding surgery, antibiotics, cannulas, and steroids in solid tumor and nononcologic diseases; and chemotherapy and neutropenia with hematologic malignancies. Even transient cannula-associated candidemia was not a benign process. Intravenous cannulas were common portals of entry (39%) in debilitated patients without cancer (59%) and were associated with high mortality (55%). Overall mortality was 59%, candidemia directly contributing to death in 75% of cases. In patients with candidemia, failure to initiate therapy with amphotericin B had a negative influence on outcome, whereas analysis of the entire group identified severity of underlying illness as the dominant cofactor influencing outcome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2749102     DOI: 10.1093/clinids/11.3.379

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  93 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  Management of Infections Caused by Candida glabrata.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.

Authors:  P Phillips; S Shafran; G Garber; C Rotstein; F Smaill; I Fong; I Salit; M Miller; K Williams; J M Conly; J Singer; S Ioannou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

4.  Production, characterization, and epitope mapping of a monoclonal antibody against aspartic proteinase of Candida albicans.

Authors:  B K Na; G T Chung; C Y Song
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

5.  Diagnosis of disseminated candidiasis in hospitalized patients using the Cand-Tec latex agglutination assay.

Authors:  M L Sanchez; M A Pfaller; I Cabezudo; M Bale; B Buschelman
Journal:  Mycopathologia       Date:  1992-06       Impact factor: 2.574

6.  Effect of challenge with Candida albicans strains with different levels of virulence on plasma proteins in burned mice.

Authors:  A N Neely; C M Childress; I A Holder
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

7.  Intravascular catheter related infections in children admitted on the paediatric wards of Mulago Hospital, Uganda.

Authors:  Patricia Nahirya; Justus Byarugaba; Sarah Kiguli; Deogratias Kaddu-Mulindwa
Journal:  Afr Health Sci       Date:  2008-12       Impact factor: 0.927

8.  Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Authors:  J Brieland; D Essig; C Jackson; D Frank; D Loebenberg; F Menzel; B Arnold; B DiDomenico; R Hare
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

9.  Structural basis for promiscuity and specificity during Candida glabrata invasion of host epithelia.

Authors:  Manuel Maestre-Reyna; Rike Diderrich; Maik Stefan Veelders; Georg Eulenburg; Vitali Kalugin; Stefan Brückner; Petra Keller; Steffen Rupp; Hans-Ulrich Mösch; Lars-Oliver Essen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

10.  Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.

Authors:  D L Horn; L Ostrosky-Zeichner; M I Morris; A J Ullmann; C Wu; D N Buell; L L Kovanda; O A Cornely
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-15       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.